Adelina Pellicer

EUROPEAN ASSOCIATION OF PERINATAL MEDICINE (EAPM) EUROPEAN MIDWIVES ASSOCIATION (EMA) Joint position statement: Caesarean delivery rates at a country level should be in the 15-20 % range

Cerebral Oximetry Monitoring in Extremely Preterm Infants

Near-infrared spectroscopy monitoring of neonatal cerebrovascular reactivity: where are we now?

The effects of cerebral oximetry in mechanically ventilated newborns: a protocol for the SafeBoosC-IIIv randomised clinical trial

Cerebral near-infrared spectroscopy monitoring (NIRS) in children and adults: a systematic review with meta-analysis

Neuromonitoring in neonatal critical care part I: neonatal encephalopathy and neonates with possible seizures

Neuromonitoring in neonatal critical care part II: extremely premature infants and critically ill neonates

Early cerebral hypoxia in extremely preterm infants and neurodevelopmental impairment at 2 year of age: A post hoc analysis of the SafeBoosC II trial

Extremely Preterm Infant Admissions Within the SafeBoosC-III Consortium During the COVID-19 Lockdown

Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial

No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC <scp>II</scp>) in preterm infants during the first days of life

Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial

The SafeBoosC Phase II Randomised Clinical Trial: A Treatment Guideline for Targeted Near-Infrared-Derived Cerebral Tissue Oxygenation versus Standard Treatment in Extremely Preterm Infants

A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial

Clinical use of cerebral oximetry in extremely preterm infants is feasible.